Melinda Wright
Family · Coeburn, VANPI 1861770380
Payments from drug & device makers
Across 67 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$178
- Novo Nordisk$164
- AbbVie$135
- AstraZeneca$68
- Exact Sciences$63
- GSK$59
- plus $424 from 16 others
What the payments were for
- Food & beverage$1,090100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 10 | $178 |
| Novo Nordisk | 11 | $164 |
| AbbVie | 9 | $135 |
| AstraZeneca | 5 | $68 |
| Exact Sciences | 3 | $63 |
| GSK | 3 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| Amarin Pharma, Inc. | 3 | $51 |
| Pfizer | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Novartis | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Johnson & Johnson | 2 | $24 |
| Abbott | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Merck | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
How this compares
$1,090 in reported general payments places this provider in the 70th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 298 | $245,377 |
| FarxigaDapagliflozin Propanediol | 82 | $73,803 |
| JanuviaSitagliptin Phosphate | 99 | $73,195 |
| OzempicSemaglutide | 72 | $69,051 |
| JardianceEmpagliflozin | 59 | $48,903 |
| RybelsusSemaglutide | 25 | $40,303 |
| LinzessLinaclotide | 44 | $38,178 |
| JanumetSitagliptin Phos/Metformin Hcl | 55 | $37,185 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $27,629 |
| MounjaroTirzepatide | 20 | $20,903 |
| MyrbetriqMirabegron | 39 | $20,631 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $19,571 |
| MultaqDronedarone Hcl | 16 | $18,768 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $17,123 |
| Spiriva RespimatTiotropium Bromide | 15 | $16,408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $47 | $245,377298 claims |
| MerckJanuvia, Janumet | $16 | $110,380154 claims |
| Novo NordiskOzempic, Rybelsus | $164 | $109,35497 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $68 | $104,110144 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $16 | $71,65286 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy | $59 | $61,15580 claims |
| AbbVieLinzess, Restasis | $135 | $46,43955 claims |
| Johnson & JohnsonXarelto | $24 | $13,54321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,332 family providers in Virginia.
Other family in Coeburn
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.